Finland-based blood testing technology provider Nightingale Health has opened a private placement round of €50m-€80m as part of its strategy to take its preventative health technology to international markets.
Carnegie is the advisor for the private placement round.
Meanwhile, the company also launched My Nightingale’s blood-testing service to deliver preventative healthcare.
Nightingale Health has received regulatory approval in Europe for its My Nightingale service.
Nightingale Health founder and chief executive officer Teemu Suna said: “We are honoured to have strong strategic partners in Japan and the US, who are not only investors in Nightingale but also business partners who are helping us take our technology to major markets.
“To make this launch as big as it deserves to be, we are raising, with the help of Carnegie, €50m-€80m in a new round of funding.”
My Nightingale provides indicators not routinely available such as inflammation, omega-3 and omega-6 fatty acids and insulin sensitivity, with predictions of a disease up to ten years in advance.
Suna said: “We are giving individuals access to health information that was previously available only for scientists. That’s because our aim is to equip people with the best tools that can help them increase their health spans and live healthy lives.”
Patients can access their blood test results via My Nightingale app, which provides the results in an easy-to-understand style.
This service is currently available in Helsinki and will soon be accessible at Nightingale Nest locations in international markets.
Suna said: “Launching the consumer service and starting the international roll-out of Nightingale’s technology is only the first step in our journey. In the coming years, we aim to expand rapidly and make Nightingale’s technology available all over the world, both to grow our business and help everyone live a healthier life.”